AMACR and cancer: To investigate whether the SLC45A2-AMACR genome-targeting reagents were also effective in human cancer cell lines that contained the gene fusion, HEPG2, which was positive for SLC45A2-AMACR, was xenografted to SCID mice subcutaneously.